Popular Stories

Surgery Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Energy
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Can Celsion Hit the Bullseye with GEN-1?

Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...

WordPress Video Lightbox Plugin